Skip to content

Clinical application of 3D printing technology in breast cancer: breast-conserving margin evaluation and new adjuvant therapy withdrawal model establishment

Clinical application of 3D printing technology in breast cancer: breast-conserving margin evaluation and new adjuvant therapy withdrawal model establishment

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039996
Enrollment
Unknown
Registered
2020-11-17
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast tumors

Interventions

Application of three-dimensional digital reconstruction models of breast and breast tumors in breast cancer surgery:three-dimensional digital reconstruction models
The new adjuvant treatment of breast cancer adopts breast MRI-3D modeling and withdrawal mode to guide the formulation of surgical plans and evaluate the efficacy:Breast MRI-3D Modeling Withdrawal Mod

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Preoperative puncture pathology diagnosed breast cancer and met the following conditions: 1. The biological behavior of the tumor was low malignant; 2. The maximum diameter of the tumor was = 2cm from the areola; 6. Tumor/breast ratio is appropriate, and it is estimated that it can maintain a better appearance after breast preservation; 7. Locally advanced cancer is reduced to stage I or II after treatment ; 8. Patients have breast-conserving requirements.

Exclusion criteria

Exclusion criteria: 1. Refusal or unable to use acceptable methods for contraception during neoadjuvant chemotherapy for breast cancer; 2. Women who breastfeed during pregnancy and after pregnancy; 3. Women with proven breast cancer metastasis; 4. Patients with sensory or motor neuropathy and confirmed by related departments; 5. People with severe cardiovascular disease, cardiopulmonary insufficiency, active infection and HIV infection; 6. History of other malignant tumors; 7. Those who are allergic to therapeutic drugs or their auxiliary materials; 8. Withdraw halfway.

Design outcomes

Primary

MeasureTime frame
Tumor size;

Countries

China

Contacts

Public ContactChen Weicai

Shenzhen Second People's Hospital

cwc0755@aliyun.com+86 13728600238

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026